Please select the option that best describes you:
Topics:
Gynecologic Oncology • Cervical Cancer
Do you include pembrolizumab for metastatic/recurrent cervical cancer per KEYNOTE-826 regardless of PDL1 status?
The NCCN guidelines only list Platinum + Taxol + Pembrolizumab +/- Bevacizumab for PDL1-positive tumors.
Answer from: at Academic Institution
PD-L1 expression is the biomarker currently approved for assessing potential responsiveness to immune checkpoint inhibitor (ICI) therapy in cervical and other malignancies. The search for better biomarkers is ongoing. With that caveat, KEYNOTE-826 was a randomized trial of chemotherapy +/- bevacizum...
Sign In or Register to read more